Let me understand??We had a decent run up, on the Q1 meeting statements. Price went from ( CDN $ ) low about;$1.60 to a high of $3.00, within a month. Within in that a run of 5 up- days, in & around 8% to 12%/ day. People were all giddy. News came out. Complicated yes. Not a buy- out or partnership. They did however indicate they would be expeditiously advance to phase 3. With both MBc treatment & Pancreatic cancer treatment. So, all good news, with more details to come in a week. The price dropped 16% to 20% depending on which numbers are used. Now! The sky is falling. Everything up to now doom & gloom etc etc. The on- going development of Pela to phase 3 has advanced. The price fell. No connection what so ever. Yes, they need a partner. Reality? The door is wide open. Roche does seem to have the lead. All, said. My gut feeling. There will not be a partnership. There will be a complete buy- out. You see folks. Pfizer does not own Taxol. BMS does have a cancer delivery patent for taxol. Roche can come in & benefit from both MBc Pela combo & their Pancreatic combo. The whole picture now makes sense. Get the Panc results, negotiate a buyout. BTW, I could be wrong about the Taxol ownership. The pharma world is cryptic at best.